Drug Trial Radar · NCT06426316
The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology.
Last checked: Nov 20, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
396
Planned (sponsor's estimate)
Start
Jun 2, 2025
Primary completion
Apr 30, 2027
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- University Hospital, Clermont-FerrandAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 23, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Migraine is a frequent and debilitating neurologic disorder. It is more frequent in women, and more prevalent in patients with autoimmune and/or inflammatory diseases such as multiple sclerosis (MS), rheumatoid arthritis (RA), Crohn's disease (CD), systemic lupus erythematosus (SLE) and endometriosis, whereas patients with long standing type 1 diabetes mellitus (T1DM) - an autoimmune but non inflammatory disease - seem to be less affected compared to the general population. Despite new migraine prevention treatments, a large number of patients remain unresponsive to currently available anti-migraine therapy and migraine pathophysiology remains unclear. Several peptides (calcitonin gene-related peptide (CGRP), pituitary adenylate cyclase activating peptide-38 (PACAP-38), vasoactive intestinal polypeptide (VIP)) and hormones (estrogens, prolactin) and the immune system play an important role in migraine pathophysiology. Among T lymphocytes, regulatory T (Treg) cells suppress inflammation. Studies have evidenced higher levels of inflammatory molecules (cytokines) in migraine patients and have suggested decreased proportions of Treg cells in migraine, as well as in MS, RA, CD and SLE, whereas inflammation declines and Treg levels seem increased in long-standing T1DM. Inflammation, which participates in migraine pain, seems to be a common factor for migraine and these diseases. However, these studies display conflicting results and further investigation is required to better understand the mechanisms behind migraine. In this study, the investigators will compare Treg levels, as well as identify Treg subpopulations and measure cytokine levels in migraine and migraine-free participants with and without an autoimmune/inflammatory disorder (MS, RA, CD, SLE, T1DM and endometriosis).
Conditions
- Migraine Disorders
- Pain
- Autoimmune Diseases
- Multiple Sclerosis
- Endometriosis
- Rheumatoid Arthritis
- Crohn Disease
- Lupus Erythematosus
Interventions
Blood testBiological
1 blood test of maximum 40 millilitres per patient
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treg cell levels in cell/microliter (cell/µL) and percentage (%) of white blood cellsTime frame: Once, at inclusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CHU de Clermont-Ferrand - Service de Neurologie
Clermont-Ferrand, AURA, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.